31.00
-21.36%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ionis Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Ionis Pharmaceuticals is based in Carlsbad, California and is incorporated in California. Its shares trade on Nasdaq under the ticker IONS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $381.4m. At that date it held total assets of $3.52bn and shareholders' equity of $489.1m.
For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.
In the last year, we delivered on our strategy to create accelerating value for all our stakeholders. With two independent commercial launches now underway, we transitioned into a fully integrated commercial-stage biotechnology company. We currently have seven marketed medicines to treat serious diseases: TRYNGOLZA (olezarsen), DAWNZERA (donidalorsen), WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen).
In addition to our currently marketed medicines, we are also positioned to independently launch two medicines in 2026, assuming regulatory approval. The FDA recently granted priority review of olezarsen for the treatment of severe hypertriglyceridemia, or sHTG, with an action date of June 30, 2026 under the Prescription Drug User Fee Act, or PDUFA. We are on track to launch olezarsen following anticipated approval. We also submitted the NDA for zilganersen in January 2026 and plan to launch zilganersen in the second half of 2026 for the treatment of Alexander disease, or AxD. We also have a rich innovative late- and mid-stage pipeline across our focus areas of neurology, cardiometabolic diseases and select areas of high patient needs.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 May 1991
- Employees
- 1,402
- Website
- ionispharma.com ↗
- Head office
- 2855 GAZELLE COURT, CARLSBAD, CA, 92010
- Incorporated in
- CA
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Joseph LoscalzoIndependent Chairman of the Board$312,162
- Dr. Brett MoniaChief Executive Officer, Director, since 2009$15.4m
- Ms. Elizabeth HougenChief Financial Officer, Executive Vice President - Finance$5.1m
- Ms. Shannon DeversChief Human Resources Officer, Executive Vice President
- Dr. C. Frank BennettExecutive Vice President, Chief Scientific Officer$958,865
- Mr. Patrick O'NeilExecutive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary$3.4m
- Mr. Joseph BaroldiExecutive Vice President, Chief Business Officer$4.0m
- Mr. Brian BirchlerExecutive Vice President, Chief Business Officer
- Dr. Richard GearyExecutive Vice President, Chief Development Officer$3.5m
- Mr. Kyle JenneExecutive Vice President, Chief Global Product Strategy Officer$4.3m
- Dr. Holly KordasiewiczExecutive Vice President and Chief Development Officer
- Mr. Eugene SchneiderExecutive Vice President, Chief Clinical Development and Operations Officer, since 2013
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 38
- Social
- 99
- Governance
- 55
- Direct emissions (scope 1)
- 2,456 t
- Energy emissions (scope 2)
- 1,841 t
- Women in the workforce
- 53.5%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ionis Pharmaceuticals Inc. benefits from several strengths that contribute to its success in the pharmaceutical industry. These include:
Weaknesses
- Despite its strengths, Ionis Pharmaceuticals Inc. also faces certain weaknesses that may hinder its growth and performance. These include:
Opportunities
- Ionis Pharmaceuticals Inc. can capitalize on various opportunities to further enhance its market position and growth prospects. These include:
Threats
- Ionis Pharmaceuticals Inc. faces several threats that could impact its business operations and future prospects. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.